Opening Hook
When Delhi hospitals run out of beds faster than Coldplay tickets, diagnostic chains become the real rockstars. Enter Chandan Healthcare — a Lucknow-based multi-vertical player that has quietly scaled to ₹232.17 crore in FY25 revenues. EBITDA margins surged to 18.7% (from 6.9% in FY23), proving pathology reports can be more profitable than pathology classes. Listed only in Feb’25, the company already flaunts 40 diagnostic centres, 360 collection centres, and a pharmacy play, spreading across 44+ cities. But can a Tier-2/Tier-3 strategy really beat the big chains in Delhi-Mumbai? Stay tuned — this is healthcare with small-town swagger and investor-sized ambition.
At a Glance
• Revenue ₹232.17 Cr – growth rate healthier than their patients
• EBITDA ₹43.38 Cr – margins upgraded like Netflix from SD to 4K
• PAT ₹22.17 Cr – 558% jump in two years, no steroids involved
• ROE 27% – doctors would kill for this recovery speed
• Debt-to-equity 0.39x – low enough to not raise BP
Management’s Key Commentary
“We serve 18+ lakh patients annually.” Translation: Uttar Pradesh alone keeps us busy enough.
“Our B2C, B2B, and B2G models ensure diversification.” Translation: Whoever pays, we test.
“Expansion into Delhi, Bhopal, and Raipur is underway.” Translation: From Lucknow chai stalls to Connaught Place lattes.
“We are focused on Tier-2 and Tier-3 markets.” Translation: Why fight Dr. Lal in Delhi when Bareilly is wide open?
“Digital adoption via Chandan
